benserazide has been researched along with Catatonic Rigidity in 8 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 3 patients with longstanding Parkinson's disease treated with Madopar or Nacom, who were not included in the study, the doses of the above drugs could be maintained or reduced by addition of deprenyl." | 2.66 | Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial. ( Grundmann, M; Schimrigk, K, 1987) |
| "In this case report, we describe a Parkinson's disease (PD) patient with limb-kinetic apraxia (LKA) in whom degeneration of the corticofugal tract (CFT) from the supplementary motor area (SMA) was observed in diffusion tensor tractography (DTT)." | 1.46 | Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report. ( Chang, MC; Lee, HD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sturchio, A | 1 |
| Gastaldi, M | 1 |
| Cariddi, LP | 1 |
| Biacchi, D | 1 |
| Espay, AJ | 1 |
| Franciotta, D | 1 |
| Versino, M | 1 |
| Mauri, M | 1 |
| Lee, HD | 1 |
| Chang, MC | 1 |
| Alam, M | 1 |
| Schmidt, WJ | 1 |
| Albani, C | 1 |
| Buck, A | 1 |
| Cunningham, MA | 1 |
| Darby, DG | 1 |
| Donnan, GA | 1 |
| Grundmann, M | 1 |
| Schimrigk, K | 1 |
| Birkmayer, W | 1 |
| Linauer, W | 1 |
| Mentasti, M | 1 |
| Riederer, P | 1 |
| Gehlen, W | 1 |
| Eisenlohr, JJ | 1 |
2 trials available for benserazide and Catatonic Rigidity
| Article | Year |
|---|---|
Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Topics: Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; | 1987 |
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dermatitis, Seborrheic; Dihydroxyphenylalanin | 1974 |
6 other studies available for benserazide and Catatonic Rigidity
| Article | Year |
|---|---|
Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies.
Topics: Adult; Autoantibodies; Autoimmune Diseases of the Nervous System; Benserazide; Dopamine Agents; Drug | 2021 |
Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report.
Topics: Anisotropy; Antiparkinson Agents; Benserazide; Diffusion Tensor Imaging; Drug Combinations; Female; | 2017 |
L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid D | 2004 |
Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Topics: Adult; Basal Ganglia; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Huma | 1993 |
Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction.
Topics: Adult; Autonomic Nervous System Diseases; Benserazide; Delayed-Action Preparations; Drug Combination | 1991 |
[Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Topics: Aged; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Evaluation; Electromyography; Humans | 1974 |